Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Perispinal etanercept: potential as an Alzheimer therapeutic.
Griffin WS.
J Neuroinflammation. 2008 Jan 10;5:3.
Related citations
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.
Tobinick EL, Gross H.
BMC Neurol. 2008 Jul 21;8:27.
Perispinal etanercept for treatment of Alzheimer's disease.
Tobinick E.
Curr Alzheimer Res. 2007 Dec;4(5):550-2. Review.
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration.
J Neuroinflammation. 2008 Jan 9;5:2.
Perispinal etanercept for neuroinflammatory disorders.
Drug Discov Today. 2009 Feb;14(3-4):168-77. Epub 2008 Dec 6. Review.
Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.
CNS Drugs. 2009 Sep;23(9):713-25. doi: 10.2165/11310810-000000000-00000. Review.
Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism.
Medscape J Med. 2008 Jun 10;10(6):135.
Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.
CNS Drugs. 2011 Feb;25(2):145-55. doi: 10.2165/11588400-000000000-00000.
Perispinal etanercept: a new therapeutic paradigm in neurology.
Expert Rev Neurother. 2010 Jun;10(6):985-1002. Review. Erratum in: Expert Rev Neurother. 2010 Jul;10(7):1232.
Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients.
Tobinick E, Davoodifar S.
Curr Med Res Opin. 2004 Jul;20(7):1075-85.
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS.
J Clin Oncol. 2005 Sep 1;23(25):5950-9.
Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports.
Tobinick EL.
Clin Ther. 2003 Aug;25(8):2279-88.
Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease.
Srivastava MD.
Res Commun Mol Pathol Pharmacol. 2001 Jul;109(1-2):125-41.
Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: a case report.
Chen YC, Wang PW, Pan TL, Bazylak G, Shen JJ.
Comb Chem High Throughput Screen. 2010 Jul;13(6):469-81.
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA, Klingman D, Hazard E, Ray S.
Clin Ther. 2009 Apr;31(4):825-35.
Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults.
Clin Ther. 2003 Apr;25(4):1211-8.
Use of etanercept in the treatment of psoriasis and psoriatic arthritis.
Fuchs BS, Hadi S.
Rev Recent Clin Trials. 2006 Sep;1(3):259-63. Review.
Perispinal TNF-alpha inhibition for discogenic pain.
Tobinick EL, Britschgi-Davoodifar S.
Swiss Med Wkly. 2003 Mar 22;133(11-12):170-7.
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C.
Clin Exp Immunol. 2008 Aug;153(2):188-95. Epub 2008 Jun 18.
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.
Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M.
Ann Rheum Dis. 2008 Oct;67(10):1444-7. Epub 2008 Jun 5.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on